MELD Score and Anti-Angiotensin Receptor Antibody Predict Long-Term Survival of Liver Re-Transplant
1Pathology and Lab Medicine, London Health Science Center, London, ON, Canada, 2Surgery, London Health Science Center, London, ON, Canada
Meeting: 2019 American Transplant Congress
Abstract number: 436
Keywords: Antibodies, Graft survival, HLA antibodies, Liver transplantation
Session Information
Session Name: Concurrent Session: Liver Transplant Complications and Retransplantation II
Session Type: Concurrent Session
Date: Tuesday, June 4, 2019
Session Time: 2:30pm-4:00pm
Presentation Time: 3:30pm-3:42pm
Location: Ballroom A
*Purpose: Recent reports indicated important while inconsistent roles of preformed donor specific antibody (DSA) to HLA in liver transplantation. Re-transplant liver patients were understudied due to worse outcome than 1st graft. Auto antibodies to Angiotensin II Type I Receptor (AT1R) have been reported to be detrimental for survival of kidney transplant but weren’t studied in liver transplantation. In this study, we try to determine the roles of preformed DSA and anti-AT1R auto antibodies in long-term survival of 2nd liver transplant.
*Methods: We retrospectively reviewed patients (1991-2018) undergoing a 2nd liver transplantation in our centre with available pre-operative serum and donor HLA typing. Patients who received ABO incompatible, multiple organ transplants or incomplete demographics were excluded. Banked sera were tested for anti-HLA antibodies with Luminex-based solid phase assays. Anti-AT1R antibodies were tested with ELISA kit. All statistical analyses were done with IBM SPSS version 25.
*Results: We included 94 patients in this study. With long follow-up up to 25 years, 48 (51.1%) patients had lost 2nd liver transplant. Preformed DSA to 2nd liver transplant were found in 34 (36.2%) patients. Surprisingly, 48 (51.1%) patients had positive anti-AT1R antibody >17U/ml; 22 (23.4%) had anti-AT1R antibody>40U/ml so extra dilutions were performed for accurate measurement. When backward stepwise methods were used to select covariates in multivariate cox regression, only three variables were left in model: MELD (Model for End-Stage Liver Disease) Score [HR=1.061 (1.019-1.105), p=0.004] and AT1R antibody>40U/ml [HR=2.241 (1.125-4.467), p=0.02] were significant risk factors for survival of the 2nd liver transplant; there was non-significant trend toward worse graft survival in male patients [HR=1.92(0.917-4.024), p=0.08]. Class, loci, strength of DSA, other patient/donor characteristics such as age, primary diseases, causes of loss 1st graft, survival of 1st graft, cold ischemia time were found to be insignificant for liver graft survival. MELD score [AUC=0.700(0.577-0.823), p=0.004] and AT1R antibody [AUC=0.64(0.528-0.753), p=0.02] quantitatively predicted graft loss in receiver operating characteristic analysis. Patients with AT1R antibody>40U/ml had significant worse survival of 2nd liver graft (p=0.035) in Kaplan-Meier analysis (Figure below).
*Conclusions: High MELD score and anti-AT1R antibody, not preformed DSA, were found to be associated with inferior outcomes of 2nd liver transplant.
To cite this abstract in AMA style:
Xu Q, Skaro A, McAlister VC. MELD Score and Anti-Angiotensin Receptor Antibody Predict Long-Term Survival of Liver Re-Transplant [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/meld-score-and-anti-angiotensin-receptor-antibody-predict-long-term-survival-of-liver-re-transplant/. Accessed November 22, 2024.« Back to 2019 American Transplant Congress